Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 28, Exegenesis Bio Inc. (abbreviation: Jiayin Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CCB International as its sole sponsor. According to the prospectus, Jiayin Biotech is a biopharmaceutical company focusing on the discovery and development of gene therapies for neurological and ophthalmic diseases. The company's pipeline also includes oligonucleotide therapies. Established in 2019, the company has built a pipeline with nine candidate products using its fully integrated internal R&D platform. Through this platform, the company has developed two core products (EXG102-031 and EXG001-307 (SMA1 type)) and one key product (EXG202) internally.

Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 28, Exegenesis Bio Inc. (abbreviation: Jiayin Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CCB International as its sole sponsor. According to the prospectus, Jiayin Biotech is a biopharmaceutical company focusing on the discovery and development of gene therapies for neurological and ophthalmic diseases. The company's pipeline also includes oligonucleotide therapies. Established in 2019, the company has built a pipeline with nine candidate products using its fully integrated internal R&D platform. Through this platform, the company has developed two core products (EXG102-031 and EXG001-307 (SMA1 type)) and one key product (EXG202) internally.